Sunitinib Malate - New Drug Approved by US FDA

International Non-Proprietary Name: Sunitinib Malate Chemical Name: N-[2-(diethylamino) ethyl]-5-[(Z)-(5-fluoro-2-oxo-1, 2-dihydro-3H-indol-3-ylidene) methyl]-2, 4-dimethyl-1H-pyyrole-3-carboxamide (2S)-2-hydroxybutanedioate Molecular Formula: C22H27FN4O2 . C4H6O5 Chemical Structure:

CAS Number: 341031-54-7 Brand Name: Sutent Dosage Form: Capsule (12.5mg, 25mg, 50mg) Applicant: Pfizer U.S. Patent No. 6,573,293 U.S. Patent Expiry: February 15, 2021 Data Exclusivity Expiry: January 26, 2011 Therapeutic Indication: Treatment of Cancer